{"id":634598,"date":"2023-01-18T18:22:01","date_gmt":"2023-01-18T18:22:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=634598"},"modified":"2023-01-18T18:22:01","modified_gmt":"2023-01-18T18:22:01","slug":"active-pharmaceutical-ingredient-market-to-grow-at-82-cagr-to-hit-2164-billion-by-2027-exclusive-report-by-marketsandmarkets","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/active-pharmaceutical-ingredient-market-to-grow-at-82-cagr-to-hit-2164-billion-by-2027-exclusive-report-by-marketsandmarkets_634598.html","title":{"rendered":"Active Pharmaceutical Ingredient Market to Grow at 8.2% CAGR to hit $216.4 Billion by 2027 – Exclusive Report by MarketsandMarkets\u2122"},"content":{"rendered":"
\n
\"Active<\/a><\/div>\n
\n
The key players in the market are Pfizer, Inc. (US), Novartis AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US)<\/div>\n<\/div>\n<\/div>\n
In 2022, Pfizer entered into an agreement with Acuitas to deliver a lipid nanoparticle delivery system for use in mRNA vaccines such as COMIRNATY ((tozinameran) and therapeutics.<\/div>\n

Active Pharmaceutical Ingredient Market<\/a><\/strong> is estimated to reach USD 216.4 billion by 2027 from USD 145.9 billion in 2022, at a CAGR of 8.2% during the forecast period according to a new report by MarketsandMarkets™.<\/strong> Factors such as the increasing incidence of chronic diseases, the growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market.<\/p>\n

Download PDF Brochure: https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=263<\/a><\/strong><\/p>\n

Browse in-depth TOC on “<\/strong> Active Pharmaceutical Ingredient Market”<\/strong><\/p>\n

241 – Tables<\/strong><\/p>\n

41- Figures<\/strong><\/p>\n

253 – Pages<\/strong><\/p>\n

“The biotech APIs segment is expected to grow at the highest CAGR during the forecast period.”<\/strong><\/p>\n

On the basis of the type of synthesis,<\/strong> the APIs market is categorized into synthetic APIs and biotech APIs. The synthetic APIs segment is estimated to account for the largest share in 2021. The biotech APIs segment is expected to grow at a higher rate over the forecast period. The demand for biotech-derived molecules is growing owing to their specificity in action.<\/p>\n

Request Sample Pages: https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=263<\/a><\/strong><\/p>\n

“North America dominated the market in 2021.”<\/strong><\/p>\n

In 2021,<\/strong> North America was expected to dominate the market, followed by Europe. Major factors driving the overall growth of the APIs market in this region include technological advancements in the manufacturing processes of APIs, the presence of major pharmaceutical & biopharmaceutical manufacturing facilities, and increasing government focus on generic drugs.<\/p>\n

The key players in the market are Pfizer, Inc. (US), Novartis AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), and AstraZeneca plc (UK).<\/p>\n

Get 10% Free Customization on this Report: https:\/\/www.marketsandmarkets.com\/requestCustomizationNew.asp?id=263<\/a><\/strong><\/p>\n

About MarketsandMarkets™:<\/strong><\/p>\n

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.<\/p>\n

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.<\/p>\n

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> MarketsandMarkets\u2122 Research Private Ltd.<\/a>
Contact Person:<\/strong> Mr. Aashish Mehra
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 18886006441
Address:<\/strong>630 Dundee Road Suite 430
City:<\/strong> Northbrook
State:<\/strong> IL 60062
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.marketsandmarkets.com\/Market-Reports\/API-Market-263.html<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

The key players in the market are Pfizer, Inc. (US), Novartis AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US) In 2022, Pfizer entered into an agreement with Acuitas … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,403,404,416],"tags":[],"class_list":["post-634598","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/634598","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=634598"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/634598\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=634598"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=634598"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=634598"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}